D. Boral Capital Reaffirms Buy Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $5.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of VolitionRx in a research report on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $3.50.

VolitionRx Stock Performance

VNRX opened at $0.33 on Monday. The firm’s fifty day moving average is $0.52 and its two-hundred day moving average is $0.60. The firm has a market cap of $35.62 million, a PE ratio of -0.92 and a beta of 1.24. VolitionRx has a twelve month low of $0.33 and a twelve month high of $0.94.

Insider Transactions at VolitionRx

In other news, CEO Cameron John Reynolds purchased 110,000 shares of VolitionRx stock in a transaction on Tuesday, October 14th. The stock was purchased at an average price of $0.51 per share, with a total value of $56,100.00. Following the transaction, the chief executive officer directly owned 2,534,847 shares in the company, valued at $1,292,771.97. The trade was a 4.54% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Guy Archibald Innes purchased 96,153 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The shares were acquired at an average cost of $0.51 per share, with a total value of $49,038.03. Following the completion of the purchase, the director directly owned 1,062,967 shares in the company, valued at approximately $542,113.17. This represents a 9.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 269,229 shares of company stock valued at $139,557. 10.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Silverberg Bernstein Capital Management LLC increased its stake in VolitionRx by 42.8% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after buying an additional 60,209 shares during the last quarter. Blair William & Co. IL acquired a new position in shares of VolitionRx during the 2nd quarter worth about $30,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of VolitionRx in the 2nd quarter valued at about $52,000. Armistice Capital LLC increased its position in shares of VolitionRx by 3.5% in the second quarter. Armistice Capital LLC now owns 8,493,074 shares of the company’s stock valued at $6,455,000 after acquiring an additional 286,644 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in VolitionRx during the third quarter worth about $28,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.